STAT

SEPTEMBER 13, 2024

  But she avoided digging into one particular subject: what she might have to endure with chemotherapy and radiation. When Rachel Guberman found out she had brain cancer, she did so much reading and Googling about the disease that she joked she had reached the end of the internet.  Continue to STAT+ to read the full story…

Chemotherapy 363

Chemotherapy Drug Development 363

STAT

OCTOBER 23, 2023

While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

Chemotherapy 289

Chemotherapy Drug Development 289

STAT

OCTOBER 20, 2023

Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.

Compounding 298

Compounding Chemotherapy Hospitals Drug Development 298

STAT

OCTOBER 23, 2023

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

Chemotherapy 289

Chemotherapy Drug Development 289

STAT

JULY 3, 2023

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.  

Chemotherapy 251

Chemotherapy Drug Development 251

European Pharmaceutical Review

JULY 4, 2023

As drug development professionals know, global health crises like the COVID-19 pandemic provide the public with valuable insights into how clinical research and regulatory processes work.

Drug Development 98

Drug Development Communication Dosage Chemotherapy 98

European Pharmaceutical Review

DECEMBER 5, 2022

The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death. The PSMAfore study.

Chemotherapy 105

Chemotherapy Labelling Compounding Drug Development 105

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine. Her husband said he had no regrets.

Vaccines 246

Vaccines Bioethics Immunity Immunization 246

Pharmaceutical Technology

SEPTEMBER 6, 2022

The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Avacta Group’s lead pre|CISION drug candidate, AVA6000, to treat soft tissue sarcoma. Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin.

Chemotherapy 98

Chemotherapy Drug Development 98

European Pharmaceutical Review

OCTOBER 26, 2023

Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months.

Chemotherapy 105

Chemotherapy Drug Development 105

European Pharmaceutical Review

NOVEMBER 28, 2022

The drug was evaluated in four Phase II/III clinical trials in patients previously given chemotherapy and/or failed radiation therapy. FTD facilitates drug development and can expedite the review of drugs for serious conditions to help address unmet medical needs.

Chemotherapy 98

Chemotherapy Immunity Immunization Drug Development 98

pharmaphorum

FEBRUARY 11, 2022

” Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.

Chemotherapy 111

Chemotherapy Drug Development 111

pharmaphorum

APRIL 27, 2021

On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively.

Chemotherapy 90

Chemotherapy Documentation Drug Development 90

pharmaphorum

DECEMBER 9, 2022

AZ estimates that approximately 70% of breast cancer tumours are considered HR-positive and HER2-low or negative and, if first-line endocrine therapies fail, their only option currently is single-agent chemotherapy.

Chemotherapy 98

Chemotherapy Drug Development 98

pharmaphorum

JUNE 8, 2021

All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6% Mei says that oncology is one of the key region-specific unmet medical needs Antengene is hoping to address with innovative drugs.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

European Pharmaceutical Review

MARCH 15, 2023

The discovery of MEN1 mutation as a resistance mechanism indicates that new drugs that targeting menin or other chromatin-associated proteins could prevent or delay revumenib resistance or treat patients who have become resistant to the drug.

Packaging 105

Packaging Chemotherapy Drug Development 105

pharmaphorum

APRIL 8, 2022

In trials, Trodelvy significantly improved both progression free survival (PFS) and overall survival (OS) in adults with locally advanced or metastatic TNBC without brain metastases – who had received at least two prior chemotherapy regimens including a taxane – compared with a range of single-agent chemotherapies.

Chemotherapy 59

Chemotherapy Drug Development 59

pharmaphorum

APRIL 11, 2022

The EAMS provides a route for clinicians and patients in desperate need of treatment options to try experimental therapies before formal approval, with the drug developer generally providing the drug at no cost. Novartis reckons in time the drug could become a $2 billion-a-year blockbuster.

Chemotherapy 52

Chemotherapy Drug Development 52

European Pharmaceutical Review

AUGUST 25, 2022

After surgery, strategic combinations of radiotherapy, chemotherapy like temozolomide, and other forms of treatment, such as immunotherapy or the use of an electric field cap, are employed. For example, radiotherapy and chemotherapy together entails up to six month? Two weeks later, patients began standard radiation and chemotherapy.

Immunity 111

Immunity Immunization Chemotherapy Packaging 111

pharmaphorum

AUGUST 5, 2021

Understanding the mechanism of PPIs and developing methods to target aberrant ones has been a key strategy in drug development. From the cluster, the protein TMEM17 was identified as a novel CSC-related gene, whose depletion can “suppress the proliferation of colorectal cancer (CRC) cells and sensitise CRC cells to chemotherapy.

Compounding 126

Compounding Chemotherapy Drug Development 126

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.

Drug Development 132

Drug Development Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 132

European Pharmaceutical Review

DECEMBER 28, 2023

As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours.

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

pharmaphorum

JULY 22, 2021

The green light for Pemazyre (pemigatinib) has been hailed by cholangiocarcinoma charity AMMF, which said it was a “major milestone” in the fight against the “Cinderella” cancer, which for years has been overlooked by drug developers.

Chemotherapy 59

Chemotherapy Labelling Drug Development 59

pharmaphorum

JANUARY 5, 2021

Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression. Meanwhile, drugs targeting TIM-3, LAG3, VISTA and STING also coming through development.

Chemotherapy 52

Chemotherapy Immunity Immunization Labelling 52

pharmaphorum

JUNE 9, 2022

In order to reduce the global healthcare impact of the evolving AMR situation, companies such as Micreos Pharmaceuticals are taking a novel and highly innovative approach to antibacterial drug development by developing targeted antimicrobial products. Antimicrobial Agents and Chemotherapy 2022. References. Herpers, P.

Drug Development 104

Drug Development Diabetes Chemotherapy 104

Pharmaceutical Technology

AUGUST 1, 2022

If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. Moreover, without effective antibiotics, epidemic bacterial infections will become common in the developed world and the risk of infections after surgery will increase.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93

pharmaphorum

SEPTEMBER 28, 2022

The time places exa-cel in pole position to become the first drug developed based on CRISPR/Cas9 gene-editing technology to reach the market.

Chemotherapy 59

Chemotherapy Drug Development 59

pharmaphorum

MARCH 30, 2021

The filing includes the UNITY-CLL phase 3 trial, a randomised study comparing the U2 combination therapy with an active control arm in which patients received Roche’s Gazyvaro plus chlorambucil chemotherapy in both treatment-naïve patients and those with relapsed/refractory disease.

Chemotherapy 52

Chemotherapy Drug Development 52

European Pharmaceutical Review

APRIL 10, 2024

For example, numerous publications have highlighted the role of the gut microbiome in improving the efficacy and diminishing the toxicity of chemotherapeutic drugs. Emerging Evidence Of The Gut Microbiome In Chemotherapy: A Clinical Review. eClinicalMedicine. 2023; 62:102111. Oh B, Boyle F, Pavlakis N, et al.

Immunity 95

Immunity Immunization Chemotherapy Diabetes 95

pharmaphorum

JUNE 12, 2022

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease.

Chemotherapy 59

Chemotherapy Drug Development 59

pharmaphorum

MAY 27, 2022

Almost all of the patients had been previously treated with chemotherapy and immunotherapy. KRAS mutations are seen in around a quarter of NSCLC tumours, with KRAS G12C mutations in particular found in around 13% of cases, but the target defied drug developers for decades.

Chemotherapy 52

Chemotherapy Drug Development 52

pharmaphorum

APRIL 23, 2021

After a string of disappointments including the failure of bintrafusp alfa , a drug developed with Germany’s Merck KGaA in lung cancer, any approval is welcome news.

Chemotherapy 52

Chemotherapy Labelling Drug Development 52

Pharmaceutical Technology

JUNE 10, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Drug Development 40

Pharmaceutical Technology

FEBRUARY 24, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Compounding Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

FEBRUARY 19, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Diabetes Drug Development 40

European Pharmaceutical Review

AUGUST 31, 2023

By reaching cancer cells that have already spread throughout the body, a targeted radiopharmaceutical treatment offers an alternative for patients with advanced cancer when standard lines of treatment, such as chemotherapy, have failed. To address these challenges, radiopharmaceutical companies have developed a variety of approaches.

Hospitals 97

Hospitals Drug Development Chemotherapy 97